Mineralocorticoid receptor interaction with SP1 generates a new response element for pathophysiologically relevant gene expression

Nucleic Acids Research

Volumn 41, Issue 17, 2013, Pages 8045-8060

  Meinel, Sandra ^a   Ruhs, Stefanie ^a   Schumann, Katja ^a   Strätz, Nicole ^a   Trenkmann, Kay ^a   Schreier, Barbara ^a   Grosse, Ivo ^a   Keilwagen, Jens ^b   Gekle, Michael ^a   Grossmann, Claudia ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b LEIBNIZ INSTITUTE OF PLANT GENETICS AND CROP PLANT RESEARCH IPK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MINERALOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; EMBRYO; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MINERALOCORTICOID RECEPTOR RESPONSE ELEMENT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ALDOSTERONE; ANIMALS; BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, MINERALOCORTICOID; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84884925588     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt581     Document Type: Article

References (51)

1. Pitt,B., Zannad,F., Remme,W.J., Cody,R., Castaigne,A., Perez,A., Palensky,J. and Wittes,J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med., 341, 709-717. (Pubitemid 29407370)
2. Pitt,B., Remme,W., Zannad,F., Neaton,J., Martinez,F., Roniker,B., Bittman,R., Hurley,S., Kleiman,J. and Gatlin,M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med., 348, 1309-1321. (Pubitemid 36384098)
3. Chrysostomou,A., Pedagogos,E., MacGregor,L. and Becker,G.J. (2006) Double-blind, Placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensinconverting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol., 1, 256-262.
4. Sartorio,C.L., Fraccarollo,D., Galuppo,P., Leutke,M., Ertl,G., Stefanon,I. and Bauersachs,J. (2007) Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension, 50, 919-925. (Pubitemid 350287535)
5. Blasi,E.R., Rocha,R., Rudolph,A.E., Blomme,E.A., Polly,M.L. and McMahon,E.G. (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int., 63, 1791-1800. (Pubitemid 36513325)
6. Brilla,C.G. and Weber,K.T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med., 120, 893-901. (Pubitemid 23002899)
7. Brown,N.J. (2008) Aldosterone and vascular inflammation. Hypertension, 51, 161-167. (Pubitemid 351159920)
8. Young,M., Fullerton,M., Dilley,R. and Funder,J. (1994) Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest., 93, 2578-2583. (Pubitemid 24177174)
9. Threadgill,D.W., Dlugosz,A.A., Hansen,L.A., Tennenbaum,T., Lichti,U., Yee,D., LaMantia,C., Mourton,T., Herrup,K., Harris,R.C. et al. (1995) Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science, 269, 230-234.
10. Sibilia,M., Kroismayr,R., Lichtenberger,B.M., Natarajan,A., Hecking,M. and Holcmann,M. (2007) The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 75, 770-787. (Pubitemid 350086174)
11. Schreier,B., Dö hler,M., Rabe,S., Schneider,B., Schwerdt,G., Ruhs,S., Sibilia,M., Gotthardt,M., Gekle,M. and Grossmann,C. (2011) Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler Thromb. Vasc. Biol., 31, 1643-1652.
12. Daub,H., Weiss,F.U., Wallasch,C. and Ullrich,A. (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature, 379, 557-560. (Pubitemid 26049585)
13. Holbro,T. and Hynes,N.E. (2004) ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol., 44, 195-217. (Pubitemid 38263839)
14. Prenzel,N., Zwick,E., Daub,H., Leserer,M., Abraham,R., Wallasch,C. and Ullrich,A. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 402, 884-888.
15. Grossmann,C., Benesic,A., Krug,A.W., Freudinger,R., Mildenberger,S., Gassner,B. and Gekle,M. (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol., 19, 1697-1710. (Pubitemid 41007884)
16. Krug,A.W., Allenhö fer,L., Monticone,R., Spinetti,G., Gekle,M., Wang,M. and Lakatta,E.G. (2010) Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-Regulated Kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension, 55, 1476-1483.
17. Mazak,I., Fiebeler,A., Muller,D.N., Park,J.K., Shagdarsuren,E., Lindschau,C., Dechend,R., Viedt,C., Pilz,B., Haller,H. et al. (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation, 109, 2792-2800. (Pubitemid 38737927)
18. Grossmann,C., Krug,A.W., Freudinger,R., Mildenberger,S., Voelker,K. and Gekle,M. (2007) Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab., 292, E1790-E1800. (Pubitemid 47084715)
19. Gomez-Sanchez,C.E., de Rodriguez,A.F., Romero,D.G., Estess,J., Warden,M.P., Gomez-Sanchez,M.T. and Gomez-Sanchez,E.P. (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology, 147, 1343-1348. (Pubitemid 43244368)
20. Grossmann,C., Freudinger,R., Mildenberger,S., Husse,B. and Gekle,M. (2008) EF domains are sufficient for nongenomic mineralocorticoid receptor actions. J. Biol. Chem., 283, 7109-7116.
21. Bokemeyer,D., Schmitz,U. and Kramer,H.J. (2000) Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int., 58, 549-558. (Pubitemid 30620004)
22. Flamant,M., Tharaux,P.L., Placier,S., Henrion,D., Coffman,T., Chatziantoniou,C. and Dussaule,J.C. (2003) Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J., 17, 327-329.
23. Francois,H., Placier,S., Flamant,M., Tharaux,P.L., Chansel,D., Dussaule,J.C. and Chatziantoniou,C. (2004) Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J., 18, 926-928.
24. Kagiyama,S., Eguchi,S., Frank,G.D., Inagami,T., Zhang,Y.C. and Phillips,M.I. (2002) Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation, 106, 909-912. (Pubitemid 34925322)
25. Griol-Charhbili,V., Fassot,C., Messaoudi,S., Perret,C., Agrapart,V. and Jaisser,F. (2011) Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension, 57, 238-244.
26. Schreier,B., Rabe,S., Schneider,B., Bretschneider,M., Rupp,S., Ruhs,S., Neumann,J., Rueckschloss,U., Sibilia,M., Gotthardt,M. et al. (2013) Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension, 61, 333-340.
27. Chen,S.-Y., Bhargava,A., Mastroberardino,L., Meijer,O.C., Wang,J., Buse,P., Firestone,G.L., Verrey,F. and Pearce,D. (1999) Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc. Natl Acad. Sci. USA, 96, 2514-2519. (Pubitemid 29117947)
28. Gumz,M.L., Stow,L.R., Lynch,I.J., Greenlee,M.M., Rudin,A., Cain,B.D., Weaver,D.R. and Wingo,C.S. (2009) The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice. J. Clin. Invest., 119, 2423-2434.
29. Kolla,V. and Litwack,G. (2000) Transcriptional regulation of the human NA/K ATPase via the human mineralocorticoid receptor. Mol. Cell. Biochem., 204, 35-40. (Pubitemid 30111755)
30. Stow,L.R., Gumz,M.L., Lynch,I.J., Greenlee,M.M., Rudin,A., Cain,B.D. and Wingo,C.S. (2009) Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1). J. Biol. Chem., 284, 30087-30096.
31. Chun,T.Y. and Pratt,J.H. (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol. Cell. Endocrinol., 239, 55-61. (Pubitemid 40848729)
32. Florian,J.A., Dorrance,A., Webb,R.C. and Watts,S.W. (2001) Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regul. Integr. Comp. Physiol., 281, R878-R886.
33. Dorrance,A.M., Osborn,H.L., Grekin,R. and Webb,R.C. (2001) Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 281, R944-R950.
34. Nakano,S., Kobayashi,N., Yoshida,K., Ohno,T. and Matsuoka,H. (2005) Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H Oxidase/ Lectin-like oxidized Low-density lipoprotein receptor-1, and Rhokinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res., 28, 925-936. (Pubitemid 43173963)
35. Schuch,R., Agelopoulos,K., Neumann,A., Brandt,B., Burger,H. and Korsching,E. (2012) Site-specific chromatin immunoprecipitation: a selective method to individually analyze neighboring transcription factor binding sites in vivo. BMC Res. Notes, 5, 109.
36. Yuan,H., Young,C., Tian,Y., Liu,Z., Zhang,M. and Lou,H. (2010) Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol. Cell. Biochem., 339, 253-262.
37. Owen,G.I., Richer,J.K., Tung,L., Takimoto,G. and Horwitz,K.B. (1998) Progesterone regulates transcription of the p21 WAF1 cyclindependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem., 273, 10696-10701. (Pubitemid 28227684)
38. Chen,K., Ou,X.M., Wu,J.B. and Shih,J.C. (2011) Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/ JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol. Pharmacol., 79, 308-317.
39. Wang,S.A., Chuang,J.Y., Yeh,S.H., Wang,Y.T., Liu,Y.W., Chang,W.C. and Hung,J.J. (2009) Heat shock protein 90 is important for sp1 stability during mitosis. J. Mol. Biol., 387, 1106-1119.
40. Petz,L.N. and Nardulli,A.M. (2000) Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol. Endocrinol., 14, 972-985. (Pubitemid 32250515)
41. Li,D., Mitchell,D., Luo,J., Yi,Z., Cho,S.G., Guo,J., Li,X., Ning,G., Wu,X. and Liu,M. (2007) Estrogen regulates KiSS1 gene expression through estrogen receptor alpha and SP protein complexes. Endocrinology, 148, 4821-4828. (Pubitemid 47481531)
42. Porter,W., Saville,B., Hoivik,D. and Safe,S. (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol., 11, 1569-1580. (Pubitemid 27435406)
43. Evans,R.M. (1988) The steroid and thyroid hormone receptor superfamily. Science, 240, 889-895.
44. Wang,C.H., Davamani,F., Sue,S.C., Lee,S.C., Wu,P.L., Tang,F.M., Shih,C., Huang,T.H. and Wu,W.G. (2011) Cell surface heparan sulfates mediate internalization of the PWWP/ HATH domain of HDGF via macropinocytosis to fine-tune cell signalling processes involved in fibroblast cell migration. Biochem. J., 433, 127-138.
45. Everett,A.D. (2001) Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev. Dyn., 222, 450-458. (Pubitemid 33042143)
46. Everett,A.D., Lobe,D.R., Matsumura,M.E., Nakamura,H. and McNamara,C.A. (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J. Clin. Invest., 105, 567-575. (Pubitemid 30146503)
47. Posch,M., Khoudoli,G.A., Swift,S., King,E.M., DeLuca,J.G. and Swedlow,J.R. (2010) Sds22 regulates aurora B activity and microtubule- kinetochore interactions at mitosis. J. Cell. Biol., 191, 61-74.
48. Jiang,Y., Scott,K.L., Kwak,S.J., Chen,R. and Mardon,G. (2011) Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling. Oncogene, 30, 3248-3260.
49. Hutten,S., Flotho,A., Melchior,F. and Kehlenbach,R.H. (2008) The Nup358-RanGAP complex is required for efficient importin alpha/beta-dependent Nuclear Import. Mol. Biol. Cell, 19, 2300-2310.
50. Gerard,B., Tait,L., Nangia-Makker,P. and Shekhar,M. (2011) Rad6B acts downstream of Wnt signaling to stabilize betacatenin: Implications for a novel Wnt/beta-catenin target. J. Mol. Signal., 6, 6.
51. Cortes,R., Rosello-Lleti,E., Rivera,M., Martinez-Dolz,L., Salvador,A., Azorin,I. and Portoles,M. (2010) Influence of heart failure on nucleocytoplasmic transport in human cardiomyocytes. Cardiovasc. Res., 85, 464-472.